Member Sign In

Should You Sell QIAGEN (QGEN) Before Earnings?

by Zacks Equity Research Published on November 03,2017

QIAGEN (QGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Can Molecular Diagnostics Drive Hologic's (HOLX) Q4 Earnings?

by Zacks Equity Research Published on November 01,2017

Hologic (HOLX) is expected to deliver solid results in Q4 on the back of the increasing market share and utilization of fully-automated Panther system.

Henry Schein Gains on Strategic Buyouts, Cost Concern a Woe

by Zacks Equity Research Published on October 13,2017

Henry Schein (HSIC) continues to grow on dental and animal health business, thanks to merger and acquisition activity. However, rising costs continue to be a burden on the company's bottom line.

NuVasive's (NUVA) PRECICE System Gets Expanded FDA Approval

by Zacks Equity Research Published on October 13,2017

NuVasive's (NUVA) latest receipt of expanded FDA 510(k) approval for PRECICE is likely to fortify its hold in the limb reconstruction and trauma market.

Abbott Banks on FDA Approvals and Buyouts, Competition Rife

by Zacks Equity Research Published on October 13,2017

The market is upbeat about Abbott's (ABT) latest initiatives.

Bruker (BRKR) at a 52-Week High: What's Driving the Stock?

by Zacks Equity Research Published on October 13,2017

The new 52-week high of Bruker (BRKR) came on the back of several new initiatives, the most recent one being the introduction of the new CE-IVD marked Fungiplex Candida fast diagnostic assay.

LabCorp (LH) Strong on Strategic Planning, Competition Rife

by Zacks Equity Research Published on October 12,2017

LabCorp (LH) grows on strong diagnostics business amid softness in the Covance drug development business.

Henry Schein Closes Merritt Buyout, Expands in Animal Health

by Zacks Equity Research Published on October 12,2017

Henry Schein (HSIC) is consistently trying to expand its Animal Health business.

CryoLife to Buy JOTEC, Preliminary Revenue Result Out for Q3

by Zacks Equity Research Published on October 12,2017

CryoLife (CRY) gained access to the $2-billion global market for stent grafts through JOTEC deal.

QIAGEN Banks on Tie-Ups & Product Launches, Competition Rife

by Zacks Equity Research Published on October 11,2017

The market is upbeat about QIAGEN's (QGEN) partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio.

Is a Beat in Store for Abbott (ABT) This Earnings Season?

by Zacks Equity Research Published on October 11,2017

Abbott's (ABT) FreeStyle Libre system receives back-to-back reimbursement approvals in several geographies, which are likely to drive growth in the Diabetes Care sales segment within Medical group.

QIAGEN Partners With CENTOGENE, Boosts Bioinformatics Suite

by Zacks Equity Research Published on October 10,2017

QIAGEN (QGEN) makes another encouraging move to expand its advanced bioinformatics portfolio and add additional capabilities, partners CENTOGENE.

QIAGEN's QFT-Plus Launch to Boost Molecular Diagnostics Arm

by Zacks Equity Research Published on October 06,2017

QIAGEN (QGEN) strengthens its highest revenue grossing segment with the launch of QuantiFERON-TB Gold Plus in the United States.

Abbott-North West London Pathology Expand in Diagnostics

by Zacks Equity Research Published on August 16,2017

Abbott Laboratories' (ABT) collaboration with North West London Pathology to strengthen its steadily growing diagnostics arm.

QIAGEN (QGEN) Beats on Earnings & Sales in Q2, Raises View

by Zacks Equity Research Published on July 28,2017

QIAGEN (QGEN) continues to bank on the Molecular Diagnostics space for growth.

QIAGEN Strengthens Cancer Research Foothold on New License

by Zacks Equity Research Published on June 06,2017

QIAGEN N.V. (QGEN) has received a worldwide license for biomarkers to be used in identifying patients who may have benefited from immune-oncology (I-O) therapies in cancer treatment.

Bristol-Myers Presents Data on Immuno-Oncology Drug Opdivo

by Zacks Equity Research Published on June 05,2017

Bristol-Myers BMY announced that the EC has approved immuno-oncology drug Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy.

QIAGEN & Bristol-Myers Squibb Partner on Cancer Research

by Zacks Equity Research Published on June 05,2017

QIAGEN N.V. (QGEN) has made significant advancement in the field of cancer research through the use of its revolutionary next-generation sequencing (NGS) technology.

Qiagen Banks on Molecular Diagnostic amid Currency Woes

by Zacks Equity Research Published on May 08,2017

On May 4, we issued an updated research report on leading molecular diagnostic company, Qiagen N.V. (QGEN).

QIAGEN (QGEN) Beats Q1 Earnings Estimates, Retains View

by Zacks Equity Research Published on May 03,2017

QIAGEN N.V. (QGEN) reported first-quarter 2017 adjusted earnings per share (considering restructuring expenses as one time item) of 22 cents, up 15.8% year over year.

Qiagen (QGEN) Down 2.6% Since Earnings Report: Can It Rebound?

by Zacks Equity Research Published on April 12,2017

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QIAGEN Releases Favorable GeneReader Results, Expands in NGS

by Zacks Equity Research Published on April 04,2017

QIAGEN N.V. (QGEN) recently has validated its GeneReader NGS System and published five new independent studies.

QIAGEN Offers JAK2 Kit in US, Grows in Molecular Diagnostics

by Zacks Equity Research Published on March 30,2017

QIAGEN N.V. (QGEN) launched ipsogen JAK2 RGQ PCR Kit in the U.S, following the Food and Drug Administration's (FDA) approval.

QIAGEN (QGEN) Earnings Meet, Sales Miss Estimates in Q4

by Zacks Equity Research Published on February 03,2017

QIAGEN N.V. (QGEN) reported fourth-quarter 2016 adjusted earnings per share (excluding restructuring expenses) of 39 cents, up 7.7% year over year.

QIAGEN (QGEN) Buys OmicSoft, Expands Bioinformatics Suite

by Zacks Equity Research Published on January 10,2017

QIAGEN N.V. (QGEN) recently announced the acquisition of Cary, NC-based OmicSoft Corporation.